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The conserved cp32 plasmid family of Borrelia burgdorferi was recently shown to be packaged into a
bacteriophage particle (C. H. Eggers and D. S. Samuels, J. Bacteriol. 181:7308–7313, 1999). This plasmid
encodes BlyA, a 7.4-kDa membrane-interactive protein, and BlyB, an accessory protein, which were previously
proposed to comprise a hemolysis system. Our genetic and biochemical evidence suggests that this hypothesis
is incorrect and that BlyA and BlyB function instead as a prophage-encoded holin or holin-like system for this
newly described bacteriophage. An Escherichia coli mutant containing the blyAB locus that was defective for the
normally cryptic host hemolysin SheA was found to be nonhemolytic, suggesting that induction of sheA by blyAB
expression was responsible for the hemolytic activity observed previously. Analysis of the structural features
of BlyA indicated greater structural similarity to bacteriophage-encoded holins than to hemolysins. Consistent
with holin characteristics, subcellular localization studies with E. coli and B. burgdorferi indicated that BlyA is
solely membrane associated and that BlyB is a soluble protein. Furthermore, BlyA exhibited a holin-like
function by promoting the endolysin-dependent lysis of an induced lambda lysogen that was defective in the
holin gene. Finally, induction of the cp32 prophage in B. burgdorferi dramatically stimulated blyAB expression.
Our results provide the first evidence of a prophage-encoded holin within Borrelia.
The spirochete Borrelia burgdorferi is the causative agent of
Lyme disease, the most prevalent arthropod-borne disease in
the United States and one that is of increasing importance
worldwide (9). If untreated, patients with Lyme disease de-
velop an array of symptoms, often culminating in debilitating
arthritis and neurologic disease (38). Clinical and animal
model studies reveal the presence of an immune response to a
variety of spirochetal antigens following infection and coloni-
zation (6, 40). However, the immune response is ineffective at
eradication of the organism and may also play a role in the
disease process in certain cases (2, 20). Down-regulation of
antigen synthesis and antigenic variation have been suggested
to be important factors in the potentiation of immune evasion
(30, 43, 44, 49).
Considerable effort has been made to elucidate the molec-
ular biology of B. burgdorferi (4, 34). Central to this effort has
been the identification of protein targets for the development
of antibodies and vaccines that can be used to diagnose and
potentially prevent Lyme disease. Efforts are also being made
to develop new and more powerful recombinant DNA tech-
niques as tools for the genetic manipulation of B. burgdorferi.
All of the B. burgdorferi genospecies reported to date contain
an ;1-Mbp linear chromosome and multiple linear and circu-
lar plasmids, the latter of which can account for up to one-third
of the organism’s coding capacity (11, 18). Plasmid-encoded
genes are believed to play an important role in virulence, since
prolonged in vitro cultivation of B. burgdorferi and loss of
plasmids result in a concomitant loss of infectivity (36, 46). A
large variety of antigens, many of which are plasmid-encoded
membrane lipoproteins, have been described to date (for ref-
erences, see references 11 and 23). However, little is known
about the precise function of most of these proteins. Specific
roles in the establishment or maintenance of infection have
been suggested for certain proteins (19, 22, 35, 49). One of the
major outer surface lipoproteins, OspA, has become the target
for vaccine trials recently (37, 39).
We previously reported the isolation and preliminary char-
acterization of the small membrane-interactive BlyA protein of
B. burgdorferi strain B31, which, together with BlyB, promoted
hemolytic activity in an Escherichia coli strain carrying this
locus (21). In B. burgdorferi B31, the blyAB locus is located in
a four-gene operon on the cp32 family of conserved circular
plasmids and the lp56 linear plasmid (11, 12, 33, 42). The
Borrelia species causing relapsing fever have also been shown
to contain cp32 plasmids carrying the blyAB operon (41). cp32
has recently been shown to be the fBB-1 prophage, and lin-
earized cp32 molecules are packaged into a bacteriophage
particle upon induction with 1-methyl-3-nitro-nitrosoguani-
dine (MNNG) (16, 17). The results presented here indicate
that the blyAB locus is likely to encode a bacteriophage holin
or holin-like system. Holins, a component of the lysis mecha-
nism for all known tailed phages, are small proteins that form
stable, nonspecific pores in the membrane, allowing endolysin
access to the peptidoglycan (1, 47, 48). In phage l, gene S
encodes the holin responsible for release of endolysin, encoded
by gene R, into the periplasm (47, 48). This report is about the
first identification and characterization of a nonstructural gene
product involved in bacteriophage function from a bacterio-
phage of spirochetes.
MATERIALS AND METHODS
Bacterial strains and plasmids. B. burgdorferi strains CA-11.2A (26) and B31
(ATCC 35210) were used. E. coli K-12 strains MM294 (27), MC4100 (10), and
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CFP201, containing the sheA::Tn5-2.1 allele (14), have already been described.
MM294 sheA::Tn5-2.1 and MC4100 sheA::Tn5-2.1 (lcI857 Sam7) were con-
structed from CFP201 by P1 transduction. MC4100 (lcI857 Sam7), MC4100
(lcI857 DSR), and pUCS105R2, a pUC19 derivative containing the lambda S
gene under the control of the lambda p9R promoter, were obtained from Ing-
Nang Wang and Ry Young (Texas A&M University). pCD1 is a pUC19 deriv-
ative containing the blyA gene under the control of the lambda p9R promoter
with the normal S gene ribosome-binding site. It was constructed utilizing a
Seamless cloning kit in accordance with the manufacturer’s (Stratagene) instruc-
tions as follows. Primers 59-GGCTCTTCATCAACGTAAGGCGTTCCTCG
ATATGC-39 and 59-AACTCTTCAGTCTTACCCCCAATAAGGGGATTT
GC-39 were used to PCR amplify pUCS105R2 exclusive of the lambda S
gene, and primers 59-CCCTCTTCCGACATGGATACTATTAAATTAACAG
AACTTC-39 and 59-CCCTCTTCCTGATTAATCTCTTTTTTTAATGTGATT
TTTGCC-39 were used to PCR amplify the coding sequence of blyA from pTG3.
The products were then cleaved with Eam1104I, and the resulting DNA frag-
ments were ligated together to give rise to pCD1, which was verified by DNA
sequence analysis. pCID552 containing the transcriptional regulatory gene mprA
has been described previously (15). pUC18-derivative plasmids pDP1 and pTG3,
which contain the blyAB locus of B. burgdorferi B31, as well as pDAK, in which
this locus is deleted, have been described previously (21). EP18 is an
MM294(pTG3) derivative containing the blyA-L10F allele (21).
Media and reagents. B. burgdorferi was routinely cultivated in Barbour-Stoen-
ner-Kelly complete medium (3) (Sigma) at 34°C with a 5% CO2 atmosphere. LB
and LB plates supplemented with appropriate antibiotics were made as described
by Miller (28). Nutrient blood agar plates containing 5% sheep erythrocytes were
purchased commercially (Remel) and spread with antibiotics as needed. DNA
restriction and modification enzymes were purchased from New England Bio-
labs. DNA primers used for PCR, mutagenesis, and DNA sequencing were
purchased commercially (Integrated DNA Technologies). Plasmid DNA was
prepared utilizing the Qiagen system. All other reagents were laboratory grade
or better and were purchased from Sigma or a comparable supplier.
Antisera. Antipeptide antibody directed against the C terminus of BlyA has
been described previously (21). For development of an antipeptide antibody
directed against the C terminus of BlyB, a 20-mer peptide (DLKFNQEGK
PIYKERTNNAK) was synthesized commercially (TANA Biologicals) and con-
jugated to keyhole limpet hemocyanin. Two New Zealand White rabbits were
injected with 1 mg of conjugate suspended in complete Freund’s adjuvant and
boosted five times over 3-week intervals with a comparable dose of peptide
suspended in incomplete Freund’s adjuvant. The antibody was affinity purified on
a Sepharose column containing the immobilized peptide.
BlyA and BlyB analysis in B. burgdorferi. Cultures of B. burgdorferi B31 and
CA-11.2A (200 ml) were grown to log phase (.107 cells ml21; A600, $0.05) and
then split into two equal aliquots. One aliquot was treated with 10 mg of MNNG
ml21 as described previously (17), and the untreated control was treated similarly
but without chemical induction. After an appropriate recovery time (;60 h), the
cells were sedimented at 8,000 3 g for 10 min at 4°C, washed in 1 ml of dPBS11
(138 mM NaCl, 2.7 mM KCl, 8.1 mM Na2HPO4, 1.5 mM KH2PO4, 0.1 g of CaCl2
liter21, 0.213 g of MgCl2 z 6 H2O liter21), and resedimented at 14,000 3 g for 5
min at 4°C in a microcentrifuge. The cell pellet was resuspended in 1 ml of
dPBS11, and the cell density (A600) was determined. The cells were sedimented
at 14,000 3 g for 5 min at 4°C and resuspended in an amount of water equal to
the A600 value multiplied by 200 ml. An equal volume of 23 sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) loading dye (125 mM
Tris-HCl [pH 8.0], 4% SDS, 20% glycerol, 10% 2-mercaptoethanol, 0.0025%
bromophenol blue) was added to each sample, which was heated at 100°C for 5
min. Aliquots were resolved by SDS-PAGE on duplicate 17.5% polyacrylamide
gels. After electrophoresis, one gel was stained with Coomassie brilliant blue and
destained while the other gel was blotted onto Immobilon-P. The membranes
were probed with BlyA, BlyB, or OspC antiserum diluted 1:5,000.
RNA analysis. Cultures of MNNG-treated and untreated B. burgdorferi B31
and CA-11.2A (100 ml) were prepared as described above. RNA extraction was
done using the Trizol reagent (Sigma) as described by the manufacturer. The
RNA pellet was resuspended in 50 to 100 ml of diethyl pyrocarbonate-treated
water, and the A260 was measured and multiplied by a factor of 40 mg ml21 and
the dilution factor to determine the RNA concentration. RNA was resolved on
a 1.2% agarose gel and transferred to Immobilon-Ny1 (Millipore) as described
previously (25). The probes for Northern hybridization were generated using the
Prime-it II labeling kit (Stratagene) in accordance with the manufacturer’s in-
structions. Probes were created using PCR (25 cycles of 92°C for 30 s, 50°C for
30 s, and 72°C for 3 min) with primers 59-CAGAACTTCTTATCAAT-39 and
59-GCCATTACCATTGCC-39 (for blyA) or 59-CCAAAGATAATGTTG-39 and
59-GATCTATGTTTGTATC-39 (for blyB). Northern hybridization was per-
formed as described previously (7).
BlyA and BlyB localization. A culture of log-phase MNNG-treated B. burg-
dorferi CA-11.2A (100 ml) was prepared and sedimented to collect cells as
described above. The cell pellet was washed in 2 ml of ice-cold TBSP (20 mM
Tris-HCl [pH 7.4], 150 mM NaCl, 5 mM EDTA, 1 mM phenylmethylsulfonyl
fluoride, 1 mg each of leupeptin, pepstatin, and aprotinin ml21) and resedi-
mented at 14,000 3 g for 10 min at 4°C. The pellet was resuspended in 2 ml of
TBSP and then sonicated on ice (eight cycles of 30 s at a setting of 3.5 with 1-min
recovery intervals). Cell lysis was evaluated by dark-field microscopy. Unlysed
cells were removed by sedimentation of the crude extract at 6,000 3 g for 10 min
at 4°C. Cell extracts were sedimented at 100,000 3 g (53,000 rpm) for 3 h at 4°C
in a TLA100.2 rotor (Beckman), and the supernatant (S100) and pellet (P100)
fractions were recovered. P100 was resuspended in a volume of TBSP equivalent
to that of the S100 fraction. Samples were analyzed by SDS-PAGE and Western
blotting as described above.
E. coli cultures (500 ml) were grown in LB supplemented with ampicillin at 100
mg ml21, when appropriate, for 15 h at 37°C. Cultures were chilled on ice, and
cells were sedimented at 15,000 3 g for 10 min at 4°C. The cell pellet was
resuspended in 10 ml of ice-cold TBSP, and cells were disrupted by three
passages through a prechilled French pressure cell (Aminco) at 16,000 lb/in2.
Unbroken cells were removed by sedimentation at 3,000 3 g for 10 min at 4°C.
A 5-ml volume of cell extract was sedimented at 100,000 3 g for 3 h at 4°C to give
rise to supernatant (S100) and membrane pellet (P100) fractions. P100 was
resuspended in an equivalent volume of TBSP. For SDS-PAGE analysis, samples
were mixed with an equal volume of loading buffer (100 mM Tris-HCl [pH 6.8],
200 mM dithiothreitol, 4% SDS, 0.2% bromophenol blue, 20% glycerol) and
heated at 100°C for 5 min and proteins were resolved by SDS–15% PAGE (24).
Gels were subjected to Western blotting (8), and the BlyA and BlyB proteins
were visualized utilizing a 1:5,000 dilution of the appropriate antibody and an
ECL kit as described by the manufacturer (Amersham).
RESULTS
blyAB is nonhemolytic in an E. coli sheA mutant. Guina and
Oliver previously hypothesized that BlyA is a hemolysin and
that BlyB is required in some manner for BlyA synthesis,
stability, or activity (21). These conclusions were based on
experiments performed with E. coli that contained the cloned
blyAB locus. However, additional genetic characterization of
this system led us to reevaluate this hypothesis. In particular,
we noted that blyAB expression occurred specifically during
stationary-phase growth, at which point the viability of the E.
coli host declined precipitously (13). Furthermore, the hemo-
lytic activity against sheep erythrocytes and the cytotoxic activ-
ity against the host strain could be uncoupled genetically in
certain blyAB mutants. These observations led us to consider
the possibility that other activities may be induced by blyAB
expression rather than resulting directly from the products of
these genes. We speculated that BlyA might not be a hemoly-
sin but rather that it could induce expression of a normally
cryptic E. coli hemolysin. In order to test this hypothesis, we
obtained a recently described E. coli mutant that is defective
for the cryptic hemolysin SheA (14). While sheA is normally
silent in most laboratory E. coli K-12 strains, it can be dere-
pressed under certain circumstances, such as by overproduc-
tion of particular transcriptional regulators, such as MprA (14,
15, 45). The appropriate plasmid-containing sheA1 and
sheA::Tn5 isogenic strains were constructed and tested for he-
molytic activity. The result indicated clearly that hemolytic
activity requires both an intact blyAB locus and a wild-type
sheA gene, since the blyAB-containing, sheA-defective host was
nonhemolytic (Table 1). Furthermore, the hemolytic pheno-
type of MM294(pTG3) on blood agar plates was visually sim-
ilar to that of MM294(pCID552), which overproduced the
transcriptional regulator MprA. These results suggest that
TABLE 1. sheA function is required for hemolytic activitya
Strain Relevantplasmid gene(s)
Presence of
hemolytic activityb
MM294(pTG3) blyAB 1
MM294(pDAK) 2
MM294 sheA::Tn5(pTG3) blyAB 2
MM294 sheA::Tn5(pDAK) 2
MM294(pCID552) mprA 1
a Strains were streaked on 5% blood agar plates supplemented with ampicillin
(100 mg ml21) and incubated at 37°C for 20 h, and then hemolysis was scored.
b 1, presence of hemolytic activity; 2, absence of hemolytic activity.
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SheA is the hemolysin in this system and that blyAB expression
serves to directly or indirectly (see Discussion) induce sheA
expression. These data also point out the utility of using the
sheA mutant as a better host for the isolation of heterologous
hemolysin determinants.
BlyA structurally resembles holins. We noted previously
that the BlyA protein is structurally similar to pore-forming
toxins such as melittin and Staphylococcus aureus delta-hemo-
lysin, since it contains a predicted hydrophobic a-helical region
followed by a positively charged C terminus (21). The pre-
dicted a-helical region, however, contains more residues than
are necessary to form a single transmembrane helix, as well as
a proline, a residue known to induce turns and disrupt helices,
at its center (31, 32). Taken together, these observations sug-
gest that BlyA actually contains two a-helical regions inter-
rupted by a proline residue. This structural model more closely
resembles another class of channel-forming proteins called
holins (48). A comparison of BlyA to two group II phage-
encoded holins is shown in Fig. 1A. The first predicted helix is
hydrophobic, while the second one is amphipathic (Fig. 1B). In
an oligomerized state, the charged surface of multiple BlyA
amphipathic helices could line the aqueous channel of the
holin pore. Holins are produced by virtually all bacteriophage
as a highly conserved mechanism to facilitate the release of
endolysin and cause cell lysis. Consistent with our hypothesis
that BlyA is a prophage-encoded holin is the recent report that
the cp32 plasmids that encode BlyA are prophages (16, 17).
BlyA possesses holin activity. In order to test whether BlyA
may possess holin activity, we utilized a genetic system devel-
oped by Wang and Young that incorporates the phage l S
gene, which encodes a holin (I.-N. Wang and R. Young, per-
sonal communication). This system involves complementation
of a thermoinducible lambda lysogen that is defective for
lambda holin (lcI857 Sam7) with a plasmid containing the test
gene of interest under the control of the lambda p9R promoter.
blyA was cloned into the appropriate plasmid vector under
lambda p9R promoter control while maintaining the S gene
ribosome-binding site (Fig. 2A). Thermoinduction of the blyA-
containing lysogen MC4100 sheA::Tn5 (lcI857 Sam7)(pCD1)
resulted in a similar onset and extent of cell lysis compared to
FIG. 1. Predictive analysis of BlyA structure and comparison to holins. (A) Predicted helices within BlyA and holins from bacteriophages 21 and T3 are shown. A 1
or 2 indicates a positively or negatively charged amino acid residue, respectively. (B) Helical wheel diagram of helix 1 (left) and helix 2 (right) of BlyA. Charged residues
are indicated as in panel A.
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the control lysogen containing lambda holin, MC4100 (lcI857
Sam7)(pUCS105R2), although the rate of lysis was somewhat
slower than that promoted by lambda holin (Fig. 2B). The fact
that the blyA-dependent lysis occurred in a sheA-defective ly-
sogen indicated that the SheA hemolysin played no role in the
observed result. Furthermore, an isogenic blyA-containing ly-
sogen that lacked both the lambda holin and endolysin genes,
MC4100 (lcI857 DSR)(pCD1), failed to undergo lysis in this
assay, indicating that cell lysis was specific for the release and
action of lambda endolysin and was not simply due to BlyA
overproduction and toxicity. This result suggests that BlyA has
holin-like activity and can transport l endolysin through the E.
coli membrane, although a less specific mechanism that results
in loss of membrane integrity allowing release of endolysin and
cell lysis to occur cannot be excluded by our experiments.
blyAB up-regulation upon phage induction. A previous at-
tempt to visualize the BlyA protein from in vitro-grown cul-
tures of B. burgdorferi by Western analysis was unsuccessful,
although a minor amount of blyAB mRNA was detectable
under these conditions (21, 33). Our hypothesis that BlyA may
be a prophage-encoded holin was further tested by assaying
blyAB expression upon prophage induction with MNNG (17).
As expected for a holin, a marked increase in the level of the
BlyA and BlyB proteins was observed in the MNNG-treated
cultures while the basal level of these two proteins was low or
undetectable in the untreated control cultures (Fig. 3). B. burg-
dorferi strain CA-11.2A constitutively produces low levels of
the BlyA protein (Fig. 3A), consistent with its constitutively
producing low levels of fBB-1 phage (17). The level of OspC,
an outer surface protein encoded on a different plasmid (25),
did not increase in either strain after MNNG treatment (data
not shown). The increased level of the BlyA and BlyB proteins
was correlated with the level of fBB-1 phage in the culture
supernatant as assayed by the presence of phage DNA (data
not shown). Furthermore, the blyAB transcript level was as-
sayed upon phage induction. This analysis revealed a substan-
tial increase in the level of blyAB mRNA after MNNG treat-
ment (Fig. 4). Again, the extent of this increase was correlated
with the level of fBB-1 DNA (linearized cp32) in the culture
supernatant (data not shown).
Subcellular localization of BlyA and BlyB. One reason that
BlyA was originally suggested to be a hemolysin was based on
its partitioning between soluble (;25%) and membrane
(;75%) fractions in E. coli (21). By contrast, holins are solely
membrane associated (48). In order to reinvestigate this issue,
fractionation studies were performed with both B. burgdorferi
and E. coli. In both organisms, BlyA was found to be entirely
membrane associated (i.e., contained solely within the P100
fraction) while BlyB was found to be a soluble protein (i.e.,
contained within the S100 fraction) (Fig. 5 and 6). To reconcile
our results with those published previously, after sedimenta-
tion of the E. coli extract, we divided the S100 into four frac-
FIG. 2. Analysis of BlyA for holin-like activity. (A) Plasmid map of pCD1.
p9R, blyA, AmpR, and ORI indicate the major rightward promoter of lambda,
the blyA gene, the b-lactamase gene, and the plasmid replicative origin, respec-
tively. (B) Strains were grown in LB supplemented with ampicillin (100 mg ml21)
at 30°C for 70 min, after which the cell density of all cultures was adjusted to an
A600 of 0.1. At an A600 of 0.2, the cultures were shifted to 42°C (0 min) for 15 min
and then placed at 37°C for monitoring of cell lysis. Similar results were obtained
in two different trials. Symbols: }, MC4100 (lcI857 Sam7)(pUCS105R2); ■,
MC4100 sheA::Tn5 (lcI857 Sam7)(pCD1); Œ, MC4100 (lcI857 DSR)(pCD1).
FIG. 3. Analysis of BlyA and BlyB protein levels in MNNG-induced B. burg-
dorferi. Cell extracts were prepared from B. burgdorferi B31 and CA-11.2A that
were treated with MNNG (1) or left untreated (2) as described in Materials and
Methods. Five microliters of each fraction was analyzed for BlyA (A) or BlyB (B)
protein content by SDS-PAGE and Western blotting.
6794 DAMMAN ET AL. J. BACTERIOL.
tions (from top to bottom), as well as a small amount of S100
that was closest to the pellet. Only the latter fraction contained
a small quantity of BlyA protein, suggesting that the prior
result was due to contamination of the soluble fraction by small
membrane fragments (Fig. 6A and data not shown). A similar
result was obtained with EP18, which contains the blyA-L10F
allele and was previously suggested to produce mostly soluble
BlyA protein (21). It is worthy of note that the BlyB protein
was found to be enriched in the bottom S100 fractions despite
the fact that most other soluble proteins were equally abun-
dant in all four S100 fractions (Fig. 6A and data not shown).
This result suggests that the small BlyB monomer (10 kDa) is
likely to oligomerize or associate with a larger protein in E.
coli. Finally, we tested whether our results were due to aggre-
gation of the BlyA protein in E. coli rather than authentic
membrane association. For this purpose, BlyA localization was
repeated using floatation sedimentation to separate mem-
branes from proteins based on their different densities. P100
was loaded at the bottom of a solution of metrizamide and
sedimented to form a density gradient that allows floatation of
membranes to the top of the gradient while proteins remain at
the bottom. The BlyA protein was present in the top fraction
along with membranes, suggesting an authentic association
with the membranes (Fig. 6B).
DISCUSSION
Previously, the blyAB locus was isolated from B. burgdorferi
B31 based on the hemolytic activity of an E. coli strain con-
taining the cloned genes (21). From genetic and biochemical
analyses of the system, Guina and Oliver suggested that BlyA
is a hemolysin and that BlyB is required in some manner for
BlyA function. In the present study, we were able to show that
the blyAB locus is nonhemolytic in an E. coli sheA mutant. This
result suggests that the otherwise cryptic SheA hemolysin is
responsible for the observed hemolytic phenotype and that
blyAB expression only serves to derepress sheA expression.
Since sheA induction normally requires production of a tran-
scriptional regulator, BlyB may be directly responsible for the
transcriptional up-regulation of sheA, particularly given its pre-
viously documented role in BlyA synthesis or stability (21). A
recent report demonstrated that a global transcriptional regu-
lator for anaerobic growth from Pasteurella haemolytica, FnrP,
also leads to sheA induction and a hemolytic phenotype in E.
coli (45). Given the complexity of growth phase-specific genetic
circuitry and the fact that blyAB expression is growth phase
dependent in E. coli (13), indirect models of sheA induction by
blyAB expression need to be considered.
The physiological role of the BlyA protein in B. burgdorferi
is more likely illustrated by the dramatic decrease in cell
growth and viability observed in the E. coli system during
stationary-phase growth (13). Indeed, sheA expression is not
ordinarily toxic to E. coli (14). We propose that BlyA has a
cytotoxic role as a bacteriophage holin or holin-like protein.
FIG. 4. Analysis of blyAB mRNA in MNNG-induced B. burgdorferi. RNA
was prepared from B. burgdorferi B31 (15 mg) and CA-11.2A (10 mg) that were
treated with MNNG (1) or left untreated (2) and analyzed by Northern hy-
bridization with a blyB probe as described in Materials and Methods. The arrow
indicates the position of the ;1.3-kb blyAB transcript. A similar result was
obtained with a blyA probe.
FIG. 5. Subcellular localization of BlyA and BlyB proteins in B. burgdorferi.
A cell extract of MNNG-treated B. burgdorferi CA-11.2A was prepared as de-
scribed in Materials and Methods. The cell extract was sedimented at 100,000 3
g for 3 h at 4°C to obtain supernatant (S100) and pellet (P100) fractions. The
pellet was resuspended in a volume of TBSP buffer equivalent to that of the
supernatant. Five microliters of each fraction was analyzed for BlyA (left) or
BlyB (right) protein content by SDS-PAGE and Western blotting.
FIG. 6. Subcellular localization of BlyA and BlyB proteins in E. coli. (A) A
cell extract of E. coli MM294(pTG3) or EP18 was prepared as described in
Materials and Methods. Cell extracts were sedimented at 100,000 3 g for 3 h at
4°C. The supernatant was divided into four fractions (C1, C2, C3, and C4), from
the top to the bottom, while the pellet (P) was resuspended in a volume of TBSP
buffer equivalent to that of the supernatant. Twenty (BlyA) or forty (BlyB)
microliters of each fraction was analyzed for BlyA and BlyB protein content by
SDS-PAGE and Western blotting. (B) Floatation sedimentation analysis of P100
from MM294(pTG3). P100 was loaded onto the bottom of a solution of metriz-
amide and subjected to floatation sedimentation analysis as described by Mitch-
ell and Oliver (29). The gradient was divided into five fractions (1 to 5), from the
top to the bottom. The positions of proteins BlyA and BlyB are shown.
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Holins are a widely distributed class of small, channel-forming
membrane proteins encoded by bacteriophage that oligomer-
ize during the phage lytic cycle to allow release of endolysin,
resulting in cell lysis. They comprise at least two membrane-
spanning helical domains and a highly charged C terminus
(48).
Several lines of evidence are consistent with this hypothesis.
First, based on the uniform size of the B. burgdorferi chromo-
some and the conserved size and distribution of the cp32 plas-
mid family, Casjens et al. proposed that cp32 is a prophage (11,
12). This suggestion has received experimental support by the
recent isolation of bacteriophage fBB-1, which contains lin-
earized cp32 molecules, from the supernatant of B. burgdorferi
strains that constitutively shed virus or can be induced to pro-
duce virus by treatment with MNNG (17). In this paper, we
show that both expression of blyAB and synthesis of the BlyA
and BlyB proteins were dramatically increased when B. burg-
dorferi was treated with MNNG; this increase correlated with
fBB-1 phage production. Second, like other holins, BlyA was
found to fractionate solely with the membrane. Third, the
structural architecture of BlyA is similar to that of other holins
in that it is likely to contain two membrane-spanning a helices
and a charged C terminus. Fourth, Western blots have dem-
onstrated a tendency of BlyA to oligomerize (13). Fifth, blyA is
one of 28 genes in a putative phage late operon (or late regu-
lon), and its location near the 39 end is a position occupied by
lysis genes in many other temperate phages (16). Finally, and
most importantly, a lysis system in which BlyA was substituted
for lambda holin resulted in a rapid-lysis phenotype character-
istic of holins. Our results provide the first indication for the
presence of a prophage-encoded holin within Borrelia. How-
ever contrary to known holins, we recently found that BlyA-
induced lysis of E. coli was prevented by treatment of the
heat-induced lambda lysogen with cyanide (C. Damman and
D. Oliver, unpublished results), which ordinarily triggers holin
oligomerization and premature cell lysis (48). Although we
emphasize the caveat that the kinetics of cell lysis mediated by
BlyA in E. coli was slower than that mediated by l S protein
and cyanide did not induce lysis, a heterologous system was
utilized to demonstrate function by complementation and the
cell lysis was dependent on the l R protein. The transport of l
endolysin through a putative Borrelia pore in an E. coli mem-
brane is rather remarkable. Additional studies employing so-
phisticated biochemical and biophysical approaches are now
warranted to confirm and extend our work, particularly given
the difficulty with genetic approaches to the study of gene
function in B. burgdorferi and the cp32 plasmid family.
Three possible roles for BlyB, which are not necessarily
mutually exclusive, can be envisioned on the basis of our work.
BlyB could be a regulatory factor, an assembly factor, or an
endolysin. The observation that BlyB is required for BlyA
production, as well as sheA derepression, is consistent with a
role as a regulatory factor, and indeed, several transcriptional
regulators have been isolated based on sheA induction (14, 15,
45). The two-way genetic interaction between blyA and blyB
noted previously (blyA mutations affect BlyB levels and vice
versa) may be explained by some sort of protein-protein inter-
action, albeit transient in nature (13, 21). This view is consis-
tent with the previous proposal that BlyB serves as a chaperone
or assembly factor for BlyA (21). Finally, in addition to a role
in BlyA synthesis or stabilization, BlyB could be an endolysin,
since endolysin genes are often located adjacent to their com-
panion holin genes (16, 48). While BlyB shows no homology to
any known endolysin and had no lytic activity in E. coli, the
phylogenetic distance between spirochetes and proteobacteria
and the difference in peptidoglycan composition between these
two groups of organisms make these observations inconclusive
(5). Additional characterization of the blyAB system in the
biology of B. burgdorferi and phage fBB-1 should clarify these
points. However, taken together, the structural and functional
data presented here suggest that the BlyA and BlyB proteins
play an important role in the lysis of B. burgdorferi cells during
the last stage of the fBB-1 lytic cycle.
ACKNOWLEDGMENTS
We thank Tina Guina for guidance throughout this project, Shannon
Kelly-Francis for help with production of the BlyB antibody, Tom
Schwan for the OspC antibody, Patti Rosa for CA-11.2A, Sherwood
Casjens for useful discussions, Ing-Nang Wang and Ry Young for
strains and advice on the holin assay, and Francisco J. del Castillo for
providing the sheA mutant.
We acknowledge the generous support of Procter and Gamble
(D.O.), the National Institutes of Health (AI41559), the Arthritis
Foundation, and the National Science Foundation (MCB-9722408)
(D.S.S.). C.H.E. was a recipient of a Predoctoral Honors Fellowship
from The University of Montana.
REFERENCES
1. Ackerman, H. W. 1998. Tailed bacteriophages: the order Caudovirales. Adv.
Virus Res. 51:135–201.
2. Akin, E., G. L. McHugh, R. A. Flavell, E. Fikrig, and A. C. Steere. 1999. The
immunoglobulin (IgG) antibody response to OspA and OspB correlates with
severe and prolonged Lyme arthritis and the IgG response to P35 correlates
with mild and brief arthritis. Infect. Immun. 67:173–181.
3. Barbour, A. G. 1984. Isolation and cultivation of Lyme disease spirochetes.
Yale J. Biol. Med. 57:521–525.
4. Barbour, A. G., and S. F. Hayes. 1986. Biology of Borrelia species. Microbiol.
Rev. 50:381–400.
5. Beck, G., J. L. Benach, and G. S. Habicht. 1990. Isolation, preliminary
chemical characterization, and biological activity of Borrelia burgdorferi pep-
tidoglycan. Biochem. Biophys. Res. Commun. 167:89–95.
6. Brandt, M. E., B. S. Riley, J. D. Radolf, and M. V. Norgard. 1990. Immu-
nogenic integral membrane proteins of Borrelia burgdorferi are lipoproteins.
Infect. Immun. 58:983–991.
7. Brown, T. 1999. Analysis of RNA by Northern and slot blot hybridization, p.
21–27. In F. M. Ausubel, R. Brent, R. E. Kingston, D. D. Moore, J. G.
Siedman, J. A. Smith, and K. Struhl (ed.), Short protocols in molecular
biology, vol. unit 4.9. John Wiley & Sons, Inc., New York, N.Y.
8. Cabelli, R. J., K. M. Dolan, L. Qian, and D. B. Oliver. 1991. Characterization
of membrane-associated and soluble states of SecA protein from wild-type
and secA51(Ts) mutant strains of Escherichia coli. J. Biol. Chem. 266:24420–
24427.
9. Campbell, G. L., C. L. Fritz, D. Fish, J. Nowakowski, R. B. Nadelman, and
G. P. Wormser. 1998. Estimation of the incidence of Lyme disease. Am. J.
Epidemiol. 148:1018–1026.
10. Casadaban, M. J. 1976. Transposition and fusion of the lac genes to selected
promoters in Escherichia coli using bacteriophage lambda and Mu. J. Mol.
Biol. 104:541–555.
11. Casjens, S., N. Palmer, R. van Vugt, W. M. Huang, B. Stevenson, P. Rosa, R.
Lathigra, G. Sutton, J. Peterson, R. J. Dodson, D. Haft, E. Hickey, M.
Gwinn, O. White, and C. M. Fraser. 2000. A bacterial genome in flux: the
twelve linear and nine circular extrachromosomal DNAs in an infectious
isolate of the Lyme disease spirochete Borrelia burgdorferi. Mol. Microbiol.
35:490–516.
12. Casjens, S., R. van Vugt, K. Tilly, P. A. Rosa, and B. Stevenson. 1997.
Homology throughout the multiple 32-kilobase circular plasmids present in
Lyme disease spirochetes. J. Bacteriol. 179:217–227.
13. Damman, C. 1999. M.S. thesis. Wesleyan University, Middletown, Conn.
14. del Castillo, F. J., S. C. Leal, F. Moreno, and I. del Castillo. 1997. The
Escherichia coli K12 sheA gene encodes a 34-kDa secreted haemolysin. Mol.
Microbiol. 25:107–117.
15. del Castillo, I., J. M. Gomez, and F. Moreno. 1990. mprA, an Escherichia coli
gene that reduces growth-phase dependent synthesis of microcins B17 and
C7 and blocks osmoinduction of proU when cloned on a high-copy-number
plasmid. J. Bacteriol. 172:437–445.
16. Eggers, C. H., S. Casjens, S. F. Hayes, C. F. Garon, C. J. Damman, D. B.
Oliver, and D. S. Samuels. 2000. Bacteriophages of spirochetes. J. Mol.
Microbiol. Biotechnol. 2:365–373.
17. Eggers, C. H., and D. S. Samuels. 1999. Molecular evidence for a new
bacteriophage of Borrelia burgdorferi. J. Bacteriol. 181:7308–7313.
18. Fraser, C. M., S. Casjens, W. M. Huang, G. G. Sutton, R. Clayton, R. Lath-
igra, O. White, K. A. Ketchum, R. Dodson, E. K. Hickey, M. Gwinn, B.
Dougherty, J.-F. Tomb, R. D. Fleischmann, D. Richardson, J. Peterson, A. R.
6796 DAMMAN ET AL. J. BACTERIOL.
Kerlavage, J. Quackenbush, S. Salzberg, M. Hanson, R. Van Vugt, N.
Palmer, M. D. Adams, J. Gocayne, J. Weidman, T. Utterback, L. Watthey,
L. McDonald, P. Artiach, C. Bowman, S. Garland, C. Fujii, M. D. Cotton, K.
Horst, K. Roberts, B. Hatch, H. O. Smith, and J. C. Venter. 1997. Genomic
sequence of a Lyme disease spirochaete, Borrelia burgdorferi. Nature 390:
580–586.
19. Fuchs, H., R. Wallich, M. M. Simon, and M. D. Kramer. 1994. The outer
surface protein A of the spirochete Borrelia burgdorferi is a plasmin(ogen)
receptor. Proc. Natl. Acad. Sci. USA 91:12594–12598.
20. Gross, D. M., T. Forsthuber, M. Tary-Lehmann, C. Etling, K. Ito, Z. A. Nagy,
J. A. Field, A. C. Steere, and B. T. Huber. 1998. Identification of LFA-1 as
a candidate autoantigen in treatment-resistant Lyme arthritis. Science 281:
703–706.
21. Guina, T., and D. B. Oliver. 1997. Cloning and analysis of a Borrelia burg-
dorferi membrane-interactive protein exhibiting haemolytic activity. Mol.
Microbiol. 24:1201–1213.
22. Guo, B. P., E. L. Brown, D. W. Dorward, L. C. Rosenberg, and M. Hook. 1998.
Decorin-binding adhesins from Borrelia burgdorferi. Mol. Microbiol. 30:711–723.
23. Kornacki, J. A., and D. B. Oliver. 1998. Lyme disease-causing Borrelia spe-
cies encode multiple lipoproteins homologous to peptide-binding proteins of
ABC-type transporters. Infect. Immun. 66:4115–4122.
24. Laemmli, U. 1970. Cleavage of structural proteins during the assembly of the
head of bacteriophage T4. Nature 227:680–685.
25. Marconi, R. T., D. S. Samuels, and C. F. Garon. 1993. Transcriptional
analyses and mapping of the ospC gene in Lyme disease spirochetes. J. Bac-
teriol. 175:926–932.
26. Margolis, N., and P. A. Rosa. 1993. Regulation of expression of major outer
surface proteins in Borrelia burgdorferi. Infect. Immun. 61:2207–2210.
27. Meselson, M., and R. Yuan. 1968. DNA restriction enzyme from E. coli.
Nature 217:1110–1114.
28. Miller, J. H. 1972. Experiments in molecular genetics. Cold Spring Harbor
Laboratory Press, Cold Spring Harbor, N.Y.
29. Mitchell, C., and D. Oliver. 1993. Two distinct ATP-binding domains are
needed to promote protein export by Escherichia coli SecA ATPase. Mol.
Microbiol. 10:483–497.
30. Montgomery, R. R., S. E. Malawista, K. J. Feen, and L. K. Bockenstedt.
1996. Direct demonstration of antigenic substitution of Borrelia burgdorferi ex
vivo: exploration of the paradox of the early immune response to outer
surface proteins A and C in Lyme disease. J. Exp. Med. 183:261–269.
31. Nilsson, I., A. Saaf, P. Whitley, G. Gafvelin, C. Waller, and G. von Heijne.
1998. Proline-induced disruption of a transmembrane a-helix in its natural
environment. J. Mol. Biol. 284:1165–1175.
32. Nilsson, I., and G. von Heijne. 1998. Breaking the camel’s back: proline-
induced turns in a model transmembrane helix. J. Mol. Biol. 284:1185–1189.
33. Porcella, S. F., T. G. Popova, D. R. Akins, M. Li, J. D. Radolf, and M. V.
Norgard. 1996. Borrelia burgdorferi supercoiled plasmids encode multicopy
tandem open reading frames and a lipoprotein gene family. J. Bacteriol.
178:3293–3307.
34. Rosa, P. A. 1997. Microbiology of Borrelia burgdorferi. Semin. Neurol. 17:5–
10.
35. Sadziene, A., A. G. Barbour, P. A. Rosa, and D. D. Thomas. 1993. An OspB
mutant of Borrelia burgdorferi has reduced invasiveness in vitro and reduced
infectivity in vivo. Infect. Immun. 61:3590–3596.
36. Schwan, T. G., W. Burgdorfer, and C. F. Garon. 1988. Changes in infectivity
and plasmid profile of the Lyme disease spirochete, Borrelia burgdorferi, as a
result of in vitro cultivation. Infect. Immun. 56:1831–1836.
37. Sigal, L. H., J. M. Zahradnik, P. Lavin, S. J. Patella, G. Bryant, R. Haselby,
E. Hilton, M. Kunkel, D. Adler-Klein, T. Doherty, J. Evans, and S. E.
Malawista. 1998. A vaccine consisting of recombinant Borrelia burgdorferi
outer-surface protein A to prevent Lyme disease. N. Engl. J. Med. 339:216–
222.
38. Steere, A. C. 1989. Lyme disease. N. Engl. J. Med. 321:586–596.
39. Steere, A. C., V. K. Sikand, F. Meurice, D. L. Parenti, E. Fikrig, R. T. Schoen,
J. Nowakowski, C. H. Schmid, S. Laukamp, C. Buscarino, and D. S. Krause.
1998. Vaccination against Lyme disease with recombinant Borrelia burgdor-
feri outer-surface lipoprotein A with adjuvant. N. Engl. J. Med. 339:209–215.
40. Stevenson, B., J. L. Bono, T. G. Schwan, and P. Rosa. 1998. Borrelia burg-
dorferi Erp proteins are immunogenic in mammals infected by tick bite, and
their synthesis is inducible in cultured bacteria. Infect. Immun. 66:2648–
2654.
41. Stevenson, B., S. F. Porcella, K. L. Oie, C. A. Fitzpatrick, S. J. Raffel, L.
Lubke, M. E. Schrumpf, and T. G. Schwan. 2000. The relapsing fever spi-
rochete Borrelia hermsii contains multiple, antigen-encoding plasmids that
are homologous to the cp32 plasmids of Lyme disease spirochetes. Infect.
Immun. 68:3900–3908.
42. Stevenson, B., W. Zückert, and D. Akins. 2000. Repetition, conservation, and
variation: the multiple cp32 plasmids of Borrelia species. J. Mol. Microbiol.
Biotech. 2:411–422.
43. Suk, K., S. Das, W. Sun, B. Jwang, S. Barthold, R. Flavell, and E. Fikrig.
1995. Borrelia burgdorferi genes selectively expressed in the infected host.
Proc. Natl. Acad. Sci. USA 92:4269–4273.
44. Sung, S. Y., J. V. McDowell, J. A. Carlyon, and R. T. Marconi. 2000. Muta-
tion and recombination in the upstream homology box-flanked ospE-related
genes of the Lyme disease spirochetes result in the development of new
antigenic variants during infection. Infect. Immun. 68:1319–1327.
45. Uhlich, G. A., P. J. McNamara, J. J. Iandolo, and D. A. Mosier. 1999.
Cloning and characterization of the gene encoding Pasteurella haemolytica
FnrP, a silent regulator of the Escherichia coli silent hemolysin SheA. J.
Bacteriol. 181:3845–3848.
46. Xu, Y., C. Kodner, L. Coleman, and R. C. Johnson. 1996. Correlation of
plasmids with infectivity of Borrelia burgdorferi sensu stricto type strain B31.
Infect. Immun. 64:3870–3876.
47. Young, R. 1992. Bacteriophage lysis: mechanism and regulation. Microbiol.
Rev. 56:430–481.
48. Young, R., and U. Blasi. 1995. Holins: form and function in bacteriophage
lysis. FEMS Microbiol. Rev. 17:191–205.
49. Zhang, J., J. Hardham, A. Barbour, and S. Norris. 1997. Antigenic variation
in Lyme disease borreliae by promiscuous recombination of VMP-like se-
quence cassettes. Cell 89:275–285.
VOL. 182, 2000 CHARACTERIZATION OF B. BURGDORFERI BlyA AND BlyB 6797
